Q-omics provides the consensus-scored CFAP97D1 profile across patient tissues and cancer cell-line models. CFAP97D1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CFAP97D1 is differentially expressed in 9, with the highest sampling consensus in KICH. Additionally, CFAP97D1 RNA expression shows 14,709 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KICH, and UVM as cancer lineages where CFAP97D1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CFAP97D1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CFAP97D1 survival associations across molecular data types. CFAP97D1 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CFAP97D1 RNA expression–survival associations across cancer types. High CFAP97D1 expression shows unfavorable associations in KIRC, THCA and ACC, but favorable associations in READ, UCS and CESC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .007). Together, the overview and detailed table identify KIRC as the clearest survival context for CFAP97D1 RNA expression.
This table summarizes CFAP97D1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CFAP97D1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CFAP97D1 shows lower tumor expression in KICH, KIRC, THCA, BRCA and LUAD and higher tumor expression in HNSC. The KICH box plot shows higher CFAP97D1 RNA expression in normal versus tumor tissue (log2 FC = −0.178, t-test p < 0.001).
This table shows molecular features associated with CFAP97D1 in patient tissues and cancer cell lines. In patient samples, CFAP97D1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, CFAP97D1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
